SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
91,600
+1,300 (1.44%)
Last updated: May 29, 2025

SK Biopharmaceuticals Revenue

SK Biopharmaceuticals had revenue of 144.38B KRW in the quarter ending March 31, 2025, with 26.67% growth. This brings the company's revenue in the last twelve months to 578.00B, up 41.64% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.

Revenue (ttm)
578.00B
Revenue Growth
+41.64%
P/S Ratio
12.41
Revenue / Employee
2.40B
Employees
241
Market Cap
7,173.49B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024547.60B192.70B54.30%
Dec 31, 2023354.89B108.71B44.16%
Dec 31, 2022246.18B-172.47B-41.20%
Dec 31, 2021418.64B392.65B1,510.23%
Dec 31, 202026.00B-97.85B-79.01%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,898.69B
Celltrion 3,662.23B
ALTEOGEN 151.65B
Yuhan 2,114.76B
HLB Co., Ltd. 74.64B
Peptron 3.15B
PharmaResearch 392.31B
LigaChem Biosciences 125.90B
Revenue Rankings